Innovent registers Phase 1 trial of IBI3034 in IgA nephropathy and healthy adults
Innovent Biologics listed a new Phase 1 study testing IBI3034 against placebo and Telitacicept, with first dosing expected October 2026.
One registry entry was posted this week for Innovent Biologics.
- IBI3034, a Phase 1 drug candidate, was registered in a trial designed as a single ascending dose study in healthy adults followed by a multiple ascending dose study in participants with primary IgA nephropathy, using Telitacicept as an open-label positive control1. The study is estimated to enroll 100 participants1 and is listed as not yet recruiting, with an estimated start date of 2026-10-15.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.